Author:
Chauhan Dharminder,Hideshima Teru,Anderson Kenneth C.
Reference30 articles.
1. Adams, J. (2002). Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol 6, 493–500.
2. Adams, J. (2004). The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4, 349–360.
3. Berkers, C. R., Verdoes, M., Lichtman, E., Fiebiger, E., Kessler, B. M., Anderson, K. C., Ploegh, H. L., Ovaa, H., and Galardy, P. J. (2005). Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods 2, 357–362.
4. Chauhan, D. and Anderson, K. C. (2003). Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications. Apoptosis 8, 337–343.
5. Chauhan, D., Li, G., Shringarpure, R., Podar, K., Ohtake, Y., Hideshima, T. and Anderson, K. C. (2003). Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 63, 6174–6177.
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献